CR20220247A - Uso de reboxetina para tratar los trastornos del sistema nervioso - Google Patents
Uso de reboxetina para tratar los trastornos del sistema nerviosoInfo
- Publication number
- CR20220247A CR20220247A CR20220247A CR20220247A CR20220247A CR 20220247 A CR20220247 A CR 20220247A CR 20220247 A CR20220247 A CR 20220247A CR 20220247 A CR20220247 A CR 20220247A CR 20220247 A CR20220247 A CR 20220247A
- Authority
- CR
- Costa Rica
- Prior art keywords
- reboxetine
- nervous system
- system disorders
- treat nervous
- esreboxetine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento se describen los métodos para el tratamiento de la narcolepsia con cataplexia, los cuales comprenden la administración de la reboxetina (la que incluye la esreboxetina) a un ser humano que lo necesite. La reboxetina (la que incluye la esreboxetina) también se puede utilizar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se dan a conocer en este documento los kits que comprenden una composición farmacéutica que comprende la reboxetina (la que incluye la esreboxetina) y las instrucciones para usar la composición farmacéutica para el tratamiento de la narcolepsia con cataplexia en un ser humano.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962943077P | 2019-12-03 | 2019-12-03 | |
US201962946295P | 2019-12-10 | 2019-12-10 | |
US16/740,329 US20200147093A1 (en) | 2018-10-15 | 2020-01-10 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US16/740,409 US11351175B2 (en) | 2018-10-15 | 2020-01-11 | Use of reboxetine to treat narcolepsy |
US16/740,411 US20200147096A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US16/740,410 US20200147095A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
PCT/US2020/062560 WO2021113163A1 (en) | 2019-12-03 | 2020-11-30 | Use of reboxetine to treat nervous system disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220247A true CR20220247A (es) | 2022-08-18 |
Family
ID=81851750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220247A CR20220247A (es) | 2019-12-03 | 2020-11-30 | Uso de reboxetina para tratar los trastornos del sistema nervioso |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP4069244A4 (es) |
JP (1) | JP2023504685A (es) |
KR (1) | KR20220108122A (es) |
CN (1) | CN114746097A (es) |
AU (1) | AU2020395082A1 (es) |
BR (1) | BR112022010677A2 (es) |
CA (1) | CA3163505A1 (es) |
CO (1) | CO2022007507A2 (es) |
CR (1) | CR20220247A (es) |
IL (1) | IL293536A (es) |
MX (1) | MX2022006630A (es) |
PE (1) | PE20230181A1 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL197983B1 (pl) * | 1999-07-01 | 2008-05-30 | Upjohn Co | Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku |
JP2003503450A (ja) * | 1999-07-01 | 2003-01-28 | ファルマシア・アンド・アップジョン・カンパニー | 高選択的ノルエピネフリン再取込みインヒビターおよびその使用方法 |
NZ581707A (en) * | 2007-05-07 | 2011-05-27 | Chelsea Therapeutics Inc | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
TWI684450B (zh) * | 2013-03-13 | 2020-02-11 | 南韓商愛思開生物製藥股份有限公司 | 猝倒症之治療 |
-
2020
- 2020-11-30 MX MX2022006630A patent/MX2022006630A/es unknown
- 2020-11-30 AU AU2020395082A patent/AU2020395082A1/en active Pending
- 2020-11-30 EP EP20895126.9A patent/EP4069244A4/en active Pending
- 2020-11-30 CR CR20220247A patent/CR20220247A/es unknown
- 2020-11-30 BR BR112022010677A patent/BR112022010677A2/pt unknown
- 2020-11-30 PE PE2022000980A patent/PE20230181A1/es unknown
- 2020-11-30 CA CA3163505A patent/CA3163505A1/en active Pending
- 2020-11-30 IL IL293536A patent/IL293536A/en unknown
- 2020-11-30 CN CN202080083484.4A patent/CN114746097A/zh active Pending
- 2020-11-30 JP JP2022533248A patent/JP2023504685A/ja active Pending
- 2020-11-30 KR KR1020227022167A patent/KR20220108122A/ko unknown
-
2022
- 2022-05-31 CO CONC2022/0007507A patent/CO2022007507A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20230181A1 (es) | 2023-02-01 |
MX2022006630A (es) | 2022-06-24 |
BR112022010677A2 (pt) | 2022-08-16 |
KR20220108122A (ko) | 2022-08-02 |
EP4069244A1 (en) | 2022-10-12 |
JP2023504685A (ja) | 2023-02-06 |
CO2022007507A2 (es) | 2022-06-21 |
EP4069244A4 (en) | 2023-12-20 |
IL293536A (en) | 2022-08-01 |
AU2020395082A1 (en) | 2022-06-09 |
CN114746097A (zh) | 2022-07-12 |
CA3163505A1 (en) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
MX2019012884A (es) | Terapia de combinacion. | |
MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
CR20210514A (es) | USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) | |
MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
MX2023004156A (es) | Terapia combinada para el tratamiento del cancer. | |
MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
WO2018209022A3 (en) | Methods of treating neuropsychiatric disorders | |
MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
JOP20200031A1 (ar) | طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة | |
MX2023003993A (es) | Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina. | |
MX2021002322A (es) | Nuevos metodos. | |
PH12017500392A1 (en) | Medical treatments based on anamorelin | |
MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
MX2021002017A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
MY186840A (en) | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy | |
WO2020079489A3 (en) | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs | |
MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
JOP20200014A1 (ar) | توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf | |
EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
CR20220247A (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
BR112022001814A2 (pt) | Métodos de tratamento de câncer multifocal | |
WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality |